Literature DB >> 12376479

Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer.

Yasuyuki Shibata1, Nobuhiro Haruki, Yoshiyuki Kuwabara, Hideyuki Ishiguro, Noriyuki Shinoda, Atsushi Sato, Masahiro Kimura, Hiroshi Koyama, Tatsuya Toyama, Tadashi Nishiwaki, Junzo Kudo, Yukio Terashita, Shigeru Konishi, Hironori Sugiura, Yoshitaka Fujii.   

Abstract

Cell cycle progression is monitored by checkpoint mechanisms to ensure the integrity of the genome and the fidelity of sister chromatid separation. Failure of such checkpoint functions results in genomic instability, a condition that predisposes cells to neoplastic transformation and tumor progression. Recently, Scolnick and Halazonetis defined a new mitotic checkpoint that acts at prophase and delays chromosome condensation in response to mitotic stress, and identified a gene, named checkpoint with FHA and ring finger (Chfr), that seems to be required for delaying prophase in human cells. In the present study, we examined human Chfr mRNA expression in 15 human esophageal cancer cell lines and 43 primary esophageal cancers to investigate the potential involvement of Chfr in the pathogenesis of esophageal cancers. We report here that a significant proportion of human esophageal cancer has loss of expression of Chfr gene. Furthermore, we found aberrant hypermethylation of the promoter region of this checkpoint gene in four of 15 (26.7%) esophageal cancer cell lines and in seven of 43 (16.3%) primary cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376479     DOI: 10.1093/carcin/23.10.1695

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  37 in total

1.  Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer.

Authors:  Shi-Lian Hu; Da-Bing Huang; Yu-Bei Sun; Lei Wu; Wei-Ping Xu; Shi Yin; Jiong Chen; Xiao-Dong Jiang; Gan Shen
Journal:  Med Oncol       Date:  2010-03-19       Impact factor: 3.064

2.  Methylation of gene CHFR promoter in acute leukemia cells.

Authors:  Hui Gong; Wengli Liu; Jianfeng Zhou; Huizhen Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

3.  Epigenetics modulates the effect of chemotherapy on gastric cancer.

Authors:  Yoshiyuki Watanabe; Fumio Itoh
Journal:  J Gastroenterol       Date:  2006-02       Impact factor: 7.527

Review 4.  Safeguarding entry into mitosis: the antephase checkpoint.

Authors:  Cheen Fei Chin; Foong May Yeong
Journal:  Mol Cell Biol       Date:  2010-01       Impact factor: 4.272

5.  Towards understanding the epigenetics of transcription by chromatin structure and the nuclear matrix.

Authors:  Rui Pires Martins; Stephen A Krawetz
Journal:  Gene Ther Mol Biol       Date:  2005

Review 6.  RNF8-dependent histone ubiquitination during DNA damage response and spermatogenesis.

Authors:  Teng Ma; Jennifer A Keller; Xiaochun Yu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2011-03-28       Impact factor: 3.848

7.  The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer.

Authors:  Yasuo Koga; Yoshihiko Kitajima; Atsushi Miyoshi; Ken Sato; Seiji Sato; Kohji Miyazaki
Journal:  J Gastroenterol       Date:  2006-02       Impact factor: 7.527

Review 8.  Review of the alterations in DNA methylation in esophageal squamous cell carcinoma.

Authors:  Yoshifumi Baba; Masayuki Watanabe; Hideo Baba
Journal:  Surg Today       Date:  2013-01-05       Impact factor: 2.549

9.  Yeast Chfr homologs retard cell cycle at G1 and G2/M via Ubc4 and Ubc13/Mms2-dependent ubiquitination.

Authors:  Greta L Loring; Kathryn C Christensen; Scott A Gerber; Charles Brenner
Journal:  Cell Cycle       Date:  2007-10-02       Impact factor: 4.534

10.  Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice.

Authors:  Zheng Fu; Kevin Regan; Lizhi Zhang; Michael H Muders; Stephen N Thibodeau; Amy French; Yanhong Wu; Scott H Kaufmann; Wilma L Lingle; Junjie Chen; Donald J Tindall
Journal:  J Clin Invest       Date:  2009-08-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.